Results obtained with the MRAP2 mutants R125H and R125C, which are found in human patients with extreme

Mutant proteins were assayed to help reveal the basis of ligand specificity, and structural comparison

A knock-in mouse expressing a non-cleavable GPR116 mutant phenocopies the pulmonary phenotype of GPR116

We found that RGS complexes with Kel1 and prefers the unphosphorylatable RGS mutant.

Targeting rhodopsin with small molecule chaperones to improve the folding and stability of the mutant

This voltage dependent potentiation is abolished in mutant animals expressing a voltage independent receptor

structural basis for this bias, we examined structural models of GPR35 and conducted experiments with mutants

CH6953755, short interfering RNA (siRNA)-mediated knockdown of YES1 and transfection of epitogue-tagged YAP mutants

Enrolled in Phase 1/2 “ELUCIDATE” Trial Assessing GTAEXS617 in Advanced Solid Tumours A Conversation with Murat

Identification of a MCMV M33 mutant (M33ΔC38) for which CREB signalling was disabled, but PLCβ activation

Cannabinoid tolerance in S426A/S430A x beta-arrestin 2 knock-out double mutant mice.

GPCR Activation and Signaling Altered Signaling and Desensitization Responses in PTH1R Mutants Associated

Intermediate-state-trapped mutants pinpoint G protein-coupled receptor conformational allostery.

A case for (mutant) G protein-coupled receptors Reviews, GPCRs, and more RGS2 and female common diseases

GPCR Binders, Drugs, and more In-depth molecular profiling of an intronic GNAO1 mutant as the basis for

Reviews, GPCRs, and more Cell-trafficking impairment in disease-associated LPA6 missense mutants and

www.ecosystem.drgpcr.com/gpcr-binders-drugs-and-more/in-depth-molecular-profiling-of-an-intronic-gnao1-mutant-as-the-basis-for-personalized-high-throughput-drug-screening

Cannabinoid Tolerance in S426A/S430A x β-Arrestin 2 Knockout Double-Mutant Mice.